JP2005526778A5 - - Google Patents

Download PDF

Info

Publication number
JP2005526778A5
JP2005526778A5 JP2003576589A JP2003576589A JP2005526778A5 JP 2005526778 A5 JP2005526778 A5 JP 2005526778A5 JP 2003576589 A JP2003576589 A JP 2003576589A JP 2003576589 A JP2003576589 A JP 2003576589A JP 2005526778 A5 JP2005526778 A5 JP 2005526778A5
Authority
JP
Japan
Prior art keywords
antigen
composition
double
stranded rna
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003576589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526778A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/007995 external-priority patent/WO2003078595A2/en
Publication of JP2005526778A publication Critical patent/JP2005526778A/ja
Publication of JP2005526778A5 publication Critical patent/JP2005526778A5/ja
Pending legal-status Critical Current

Links

JP2003576589A 2002-03-15 2003-03-14 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法 Pending JP2005526778A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36449002P 2002-03-15 2002-03-15
US41221902P 2002-09-20 2002-09-20
PCT/US2003/007995 WO2003078595A2 (en) 2002-03-15 2003-03-14 Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response

Publications (2)

Publication Number Publication Date
JP2005526778A JP2005526778A (ja) 2005-09-08
JP2005526778A5 true JP2005526778A5 (https=) 2006-04-27

Family

ID=28045408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003576589A Pending JP2005526778A (ja) 2002-03-15 2003-03-14 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法

Country Status (6)

Country Link
US (1) US20050222060A1 (https=)
EP (1) EP1485403A4 (https=)
JP (1) JP2005526778A (https=)
AU (1) AU2003218181A1 (https=)
CA (1) CA2479187A1 (https=)
WO (1) WO2003078595A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258712A3 (en) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
WO2004087877A2 (en) 2003-03-26 2004-10-14 Astral Inc. Selected rna motifs to include cell death and/or apoptosis
ES2911034T3 (es) * 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
WO2008156753A1 (en) * 2007-06-18 2008-12-24 Hemispherx Biopharma Early intervention of viral infections with immune activators
ES2393163T3 (es) * 2007-12-18 2012-12-19 Athera Biotechnologies Ab Compuestos y métodos para el tratamiento de enfermedad vascular
AU2009239655B2 (en) 2008-04-25 2014-05-22 Innate Pharma Improved TLR3 agonist compositions
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
PL3892295T3 (pl) * 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2019152884A1 (en) * 2018-02-02 2019-08-08 University Of Washington Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US5906980A (en) * 1987-07-17 1999-05-25 Hem Research Inc. Treatment of hepatitis with mismatched dsRNA
US5683986A (en) * 1987-08-12 1997-11-04 Hemispherx Biopharma Inc. Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment
US5593973A (en) * 1987-09-04 1997-01-14 Hemispherx Biopharma Inc. Treatment of viral hepatitis with mismatched dsRNA
ATE130765T1 (de) * 1989-02-24 1995-12-15 Univ California Gentechnologisch veränderte immunglobuline.
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
ZA908037B (en) * 1989-10-11 1991-09-25 Hem Res Inc Protection from shock subsequent to injury by double-standed rnas
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
DE69535243T2 (de) * 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) * 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
GB9501079D0 (en) * 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
AR013269A1 (es) * 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
WO2001036641A2 (en) * 1999-11-02 2001-05-25 Chiron Corporation DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO
DE60038189T2 (de) * 2000-05-25 2009-02-19 Fuji Xerox Co., Ltd. Toner und bilderzeugungsmethode
WO2001093902A2 (en) * 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules

Similar Documents

Publication Publication Date Title
JP2005526778A5 (https=)
CHAN et al. Legend of hepatitis B vaccination: the Taiwan experience
NO20015073L (no) Vaksiner
FI1897548T4 (fi) T-solujen säätely
WO2006050250A3 (en) Dose forms comprising vx-950 and their dosage regimen
NZ597915A (en) Combination therapy for treatment of immune disorders
WO2006041866A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
IL276515B1 (en) PD–L1-specific antibodies and methods of using them
JP2007522094A5 (https=)
JP2002506648A5 (https=)
JP2007524613A5 (https=)
JP2015513535A5 (https=)
JP2012504602A5 (https=)
JP2020533302A5 (https=)
JP2019532047A5 (https=)
Soriano et al. Treatment of hepatitis delta and HIV infection
JP2013028611A5 (https=)
JP2017519762A5 (https=)
JP2007504268A5 (https=)
WO2003078595B1 (en) Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
Niu et al. Synergistic and additive effects of cimetidine and levamisole on cellular immune responses to hepatitis B virus DNA vaccine in mice
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
JP2004523538A5 (https=)
Kolb et al. Effective use of tocilizumab for the treatment of steroid‐refractory gastrointestinal acute graft versus host disease in a child with very high levels of serum interleukin‐6
JP2008539169A5 (https=)